LINK?PING, Sweden--(BUSINESS WIRE)--A focused review titled “Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?” was recently published in the renowned cardiovascular scientific journal, Circulation. Authored by AMRA Medical’s Dr. Jennifer Linge, professor Andreas Birkenfeld of University Hospital Tübingen, and associate professor Ian Neeland of University Hospitals Cleveland, the article discusses several aspects of the response associated with weight loss with respect to muscle health..

瑞典林克平——（商業(yè)新聞短訊）——一篇題為“肌肉質量和胰高血糖素樣肽-1受體激動劑：對減肥的適應性或不適應性反應”的重點評論最近發(fā)表在著名的心血管科學雜志《循環(huán)》上。這篇文章由AMRA Medical的Jennifer Linge博士、蒂賓根大學醫(yī)院的Andreas Birkenfeld教授和克利夫蘭大學醫(yī)院的Ian Neeland副教授撰寫，討論了與肌肉健康相關的減肥反應的幾個方面。。

As pharmaceutical treatments, such as GLP-1 agonists, are reaching weight reductions of magnitudes close to those achieved through bariatric surgery, the concerns regarding a possible adverse impact on muscle health are growing. In light of this, the experts aimed to address whether muscle-related changes associated with weight loss treatments such as GLP-1 receptor agonists may be maladaptive (i.e., adversely impacting muscle health/function), adaptive (i.e., a physiologic response to weight loss maintaining or minimally affecting muscle health/function), or perhaps an enhanced response to weight loss (i.e., improved muscle health/function following treatment)..

隨著藥物治療（如GLP-1激動劑）的體重減輕程度接近減肥手術所達到的程度，人們越來越擔心可能對肌肉健康產生不利影響。有鑒于此，專家們旨在解決與減肥治療相關的肌肉相關變化（如GLP-1受體激動劑）是否可能是適應不良（即對肌肉健康/功能產生不利影響），適應性（即對減肥的生理反應維持或對肌肉健康/功能的影響最?。?，或者可能是對減肥的增強反應（即治療后肌肉健康/功能的改善）。。

Historical studies of GLP-1-based therapies and body composition have reported absolute and/or relative changes in total body lean mass. Results vary greatly from study to study, likely due to, e.g., variations in population characteristics, study durations, and dosing, but also because of the individual heterogeneity in lean mass composition - comprising not only muscle mass, but also organs, bone, fluids, and water in fat tissue..

基于GLP-1的療法和身體成分的歷史研究報告了全身瘦體重的絕對和/或相對變化。不同研究的結果差異很大，可能是由于人群特征，研究持續(xù)時間和劑量的變化，也可能是由于瘦體重組成的個體異質性-不僅包括肌肉質量，還包括脂肪組織中的器官，骨骼，液體和水。。

The heterogeneity in past study results makes it difficult for clinicians and researchers to determine what is “normal” or “healthy” weight reduction. However, recent studies in this area have utilized gold-standard MRI-based technology and muscle composition assessments including muscle volume (both in liters and as a sex-, height-, weight-, and BMI invariant z-score describing ‘relative or adequate muscle mass’) as well as muscle fat infiltration, providing muscle-specific data on the effect of incretin-based treatments.

。然而，最近在這一領域的研究利用了金標準的基于MRI的技術和肌肉組成評估，包括肌肉體積（以升為單位，以及描述“相對或足夠肌肉質量”的性別，身高，體重和BMI不變z評分）以及肌肉脂肪浸潤，提供了關于腸降血糖素治療效果的肌肉特異性數(shù)據(jù)。

The authors conclude that the introduction of objective and comprehensive ways of assessing muscle health (including accurate and meaningful assessments of muscle quantity, composition, function, mobility, and strength) is important for the future development of GLP-1-based therapies and patient-centric treatment optimization..

作者得出結論，引入客觀和全面的評估肌肉健康的方法（包括對肌肉數(shù)量，組成，功能，活動性和力量的準確和有意義的評估）對于基于GLP-1的療法的未來發(fā)展和以患者為中心的治療優(yōu)化是重要的。。

As drug development activity increases in the obesity indication and branches out towards aiming for weight reduction with preserved muscle health, it is paramount to include measures such as the muscle volume z-score and muscle fat infiltration, in order to understand the safety and benefit of drugs achieving significant and/or rapid weight reduction.

隨著藥物開發(fā)活動在肥胖適應癥中的增加，并轉向以保持肌肉健康為目標的減肥，至關重要的是要包括肌肉體積z評分和肌肉脂肪浸潤等措施，以了解藥物的安全性和益處實現(xiàn)顯著和/或快速減肥。

AMRA is committed to pioneering not only the development of powerful biomarker methodologies such as the muscle volume z-score in order to augment drug development, but also to the generation of normative data, providing context to future clinical trials and basis for interpretation of clinical benefits related to improving/maintaining muscle health.

AMRA不僅致力于開發(fā)強大的生物標志物方法，如肌肉體積z評分，以增加藥物開發(fā)，而且致力于生成規(guī)范數(shù)據(jù)，為未來的臨床試驗提供背景，并為解釋與改善/維持肌肉健康有關的臨床益處奠定基礎。

These initiatives will help ensure that the obesity field develops products with safety and the impact on vulnerable populations in mind..

這些舉措將有助于確保肥胖領域開發(fā)安全的產品，并考慮到對弱勢人群的影響。。

You can read the full article to learn more about MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health here.

您可以閱讀整篇文章，以了解更多有關基于MRI的肌肉評估及其在確定藥物減肥與肌肉健康之間關系中的用途。

Learn more about AMRA Medical and how the use of MRI-based fat distribution and muscle composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.

了解有關AMRA Medical的更多信息，以及如何使用基于MRI的脂肪分布和肌肉成分分析來推進包括肥胖在內的代謝性疾病的疾病研究。

About AMRA Medical

關于AMRA Medical

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.

AMRA Medical是一家健康信息學和精準醫(yī)學公司，開創(chuàng)了人體成分分析的先河，為推進臨床研究和患者護理計劃提供了前沿解決方案。AMRA的金標準技術提供多種脂肪和肌肉生物標志物，這些標志物僅來自快速的全身MRI掃描。

AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform..

AMRA致力于通過其創(chuàng)新平臺提供支持服務，推動變革性護理，簡化研究和臨床護理環(huán)境中的重要決策。。

Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.

了解有關AMRA Medical基于MRI的解決方案的更多信息，請訪問https://amramedical.com/solutions，或與我們的專家團隊聯(lián)系，在info@amramedical.com.

Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.

關注LinkedIn上的AMRA，了解身體成分和精準醫(yī)學的最新更新。

相關知識

我漂亮的瘦子6：探討瘦身背后的心理健康、飲食科學與現(xiàn)代審美觀變化
適于健康照明研究的光與情緒實驗方法探討
你真是瘦了：體型變化背后的健康與心理探討
環(huán)境與健康雜志
惡性循環(huán)的警示：肥胖與焦慮的共生
肥胖與心理健康：肥胖與抑郁、焦慮之間是什么樣的關系？
康復醫(yī)學與治療醫(yī)學關系的探討
孫超主任/王曉雨醫(yī)師團隊發(fā)現(xiàn)：肝硬化失代償期患者肌肉脂肪變性與各種體成分異常的關系
自然與健康的關系：自然療法、探索身心平衡
心理健康與減肥的關系

網(wǎng)址: 適應變化：循環(huán)雜志的新焦點綜述探討了減肥與肌肉健康之間的關系 http://www.u1s5d6.cn/newsview219815.html